Anbio Biotechnology Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	5.35	11.76	9.69	7.1	4.18
Short-Term Investments	8.08	-	-	1.57	-
Cash & Short-Term Investments	13.43	11.76	9.69	8.67	4.18
Cash Growth	30.25%	21.40%	11.75%	107.33%	-
Receivables	3.72	1.06	1.88	-	0.72
Inventory	-	-	-	0.35	-
Prepaid Expenses	10.54	5.71	4.17	4.92	0.02
Other Current Assets	-	0	0	0	0
Total Current Assets	27.68	18.53	15.75	13.94	4.92
Property, Plant & Equipment	-	-	-	0.01	-
Long-Term Deferred Charges	-	0.39	0.04	-	-
Other Long-Term Assets	-	-	0.02	0	-
Total Assets	27.68	18.92	15.81	13.96	4.92
Accounts Payable	0.06	1.63	0.83	1.41	1.89
Accrued Expenses	-	-	0.13	-	-
Other Current Liabilities	0.07	0.1	0.03	0	0.49
Total Current Liabilities	0.13	1.73	0.99	1.41	2.38
Total Liabilities	0.13	1.73	0.99	1.41	2.38
Common Stock	0.01	0.01	0.01	-	-
Additional Paid-In Capital	6.56	0	0	-	-
Retained Earnings	20.97	17.17	14.8	12.55	2.54
Shareholders' Equity	27.55	17.19	14.82	12.55	2.54
Total Liabilities & Equity	27.68	18.92	15.81	13.96	4.92
Net Cash (Debt)	13.43	11.76	9.69	8.67	4.18
Net Cash Growth	30.25%	21.40%	11.75%	107.33%	-
Net Cash Per Share	0.31	0.28	0.45	-	-
Filing Date Shares Outstanding	43.89	43.89	42.29	-	-
Total Common Shares Outstanding	43.89	42.29	42.29	-	-
Working Capital	27.55	16.8	14.76	12.53	2.54
Book Value Per Share	0.63	0.41	0.35	-	-
Tangible Book Value	27.55	17.19	14.82	12.55	2.54
Tangible Book Value Per Share	0.63	0.41	0.35	-	-

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q